[Anti-retroviral treatment. Treatment modification: toxicity management].
Ocaña
I
I
Hospital General Vall d'Hebron, Barcelona.
Laguna
F
F
Pulido
F
F
Bascuñana
A
A
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016049:Didanosine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology; D004359:Drug Therapy, Combination; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D015658:HIV Infections / Q000188:drug therapy*; D006402:Hematologic Diseases / Q000139:chemically induced / Q000628:therapy; D006801:Humans; D009135:Muscular Diseases / Q000139:chemically induced; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016047:Zalcitabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine
Modificaciones del tratamiento: manejo de toxicidades.